AU2018221613A1 - Method for purification of whey proteins - Google Patents
Method for purification of whey proteins Download PDFInfo
- Publication number
- AU2018221613A1 AU2018221613A1 AU2018221613A AU2018221613A AU2018221613A1 AU 2018221613 A1 AU2018221613 A1 AU 2018221613A1 AU 2018221613 A AU2018221613 A AU 2018221613A AU 2018221613 A AU2018221613 A AU 2018221613A AU 2018221613 A1 AU2018221613 A1 AU 2018221613A1
- Authority
- AU
- Australia
- Prior art keywords
- whey
- lactalbumin
- alpha
- cation exchanger
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 65
- 235000021119 whey protein Nutrition 0.000 title claims description 24
- 238000000746 purification Methods 0.000 title claims description 9
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 59
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 56
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 55
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 53
- 239000005862 Whey Substances 0.000 claims abstract description 49
- 150000001768 cations Chemical class 0.000 claims abstract description 29
- 238000011068 loading method Methods 0.000 claims abstract description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 238000010828 elution Methods 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 102000008192 Lactoglobulins Human genes 0.000 claims description 17
- 108010060630 Lactoglobulins Proteins 0.000 claims description 17
- 239000011324 bead Substances 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000011067 equilibration Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 238000011210 chromatographic step Methods 0.000 abstract description 6
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 239000007983 Tris buffer Substances 0.000 description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 235000013350 formula milk Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000006167 equilibration buffer Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
Abstract
The invention describes a method of purifying alpha-lactalbumin from whey with a single chromatographic step. The method involves adjusting the pH of the whey and loading the whey onto a cation exchanger for a prolonged period of time/volume after which a highly pure alpha-lactalbumin can be eluted from the column. This method uses only a single chromatography step to achieve a high purity alpha-lactalbumin eluate and allows the alpha-lactalbumin depleted whey to be further processed for example pH adjusted back to a target set point, dried and recovered as a whey product or otherwise further processed.
Description
Title: Method for purification of whey proteins
Field of the invention
A method for purifying whey proteins and alpha-lactalbumin is described. This method involves separation and purification of the alpha-lactalbumin from whey (including different whey types, e.g. sweet, sour or ideal) to produce highly pure alpha-loactalbumin or alpha-lactalbumin-enriched whey protein isolate in a process utilizing a single chromatography step in which the nutritional and functional properties of the protein are retained allowing for use such as an ingredient in various food products, infant formulas, adult nutritional formulas, sport formulas, medical formulas enteral formulas and other specialist nutrition, nutraceutical and pharmaceutical products. In addition, this method also allows the alpha-lactalbumin depleted whey to be further processed to extract other whey proteins and produce other whey protein products.
Background of the invention
Whey is the liquid component of milk and is typically obtained during the manufacture of cheese or casein as a result of separation and clarification from curds or casein. Whey is composed of water, lactose, salts, residual fats and several proteins. Whey proteins possess interesting nutritional, functional, physiological, and pharmaceutical properties and are divided into two principal groups: the globulin protein fraction containing mainly beta-lactoglobulin and immunoglobulins; and the albumin fraction including alfa-lactalbumin and serum albumin.
Alpha-lactalbumin is a globular protein composed of 123 amino acids it is found in both human and bovine milk for which it has 74% conserved amino acid sequence homology. Alpha-lactalbumin occurs as an acidic single chain protein with a molecular mass corresponding to 14070 Da in human milk and 14178 Da in bovine milk. In humans alpha-lactalbumin is the dominant whey protein and makes up approximately -75% of total whey protein and -40% by weight of total protein in bovines however alpha lactalbumin is quantitatively the 2nd most important protein in whey making up -25% of total whey protein and -5% by weight of total protein superseded by the dominant protein present in bovine whey beta-lactoglobbulin which is considered to be absent in human milk REF.
Whey proteins have different utilities such as an ingredient in various food products, infant formulas, adult nutritional formulas, sport formulas, medical formulas enteral formulas and other specialist nutrition, nutraceutical and pharmaceutical products. Of the whey proteins alpha-lactalbumin has
WO 2018/149809
PCT/EP2018/053506 been shown to exhibit a number of important nutritional and functional characteristics due to its amino acid content and functional properties (Marshall, 2004, K. Lisak Jakopovic et al, 2015).
As there is a number of commercial applications and products that already use alpha-lactalbumin and new human health and nutrition applications are being generated, there are several processes for purification of whey proteins and alpha-lactalbumin including ultrafiltration, heat precipitation, and ion exchange methods.
Ultrafiltration methods use membranes which allow for separation of proteins and molecules based on their physical size allowing proteins and molecules up to a certain size to pass through into the permeate these methods can be effective at performing separations when no proteins or molecules of similar size exist in the feed material however to isolate molecules larger and smaller multiple steps are required this method is described in US. Pat. No. 5,008,376 (Bottomley) and further in US. Patent 6,613,377 (Chao Wu) which further applies adjustment of the pH to below 4 to further increase efficiency of the method. US 6,613,377 B2 describes a whey treatment process for specifically enriching alpha lactalbumin. A whey protein product is acidified to a pH below 4, concentrated and then the desired alpha lactalbumin is precipitated to form a low calcium product.
Heat precipitation is another method and involves adjusting the pH and heating the whey to denature and precipitate the protein of interest US. Pat. No. 5,455,331 (Pearce) describes use of this method for producing an alphalactalbumin product.
Ion exchange methods involve contacting the whey with an anion or cation exchanger so as to selectively retain a protein fraction. Such a process is described in US. Pat. No. 5,077,067 (Thibault which selectively removes lactoglobulins from whey and US 5,756,680 (Sepragen) which applies a sequential process to separate different proteins in the whey to other methods including El-Sayed & Chase 2009 and 2010 which describe a two- step chromatography process to produce alphalactalbumin and beta-lactoglobulin at room temperature to purify alpha-lactalbumin (ALA) and betalactoblobulin (BLG) from whey concentrate.
The above methods require multiple steps, long processing times, many buffers or chemical treatments, cause denaturation to the protein and are unable to deliver a product with as high purity and yield. As such there is a need for improved methods that allow for improved processing for purification of whey proteins, especially in producing alpha-lactalbumin.
Summary of the invention
The present invention provides a novel method for purification of alpha-lactalbumin (ALA). The invention describes a method of purifying alpha-lactalbumin to a high purity from whey in a single
WO 2018/149809
PCT/EP2018/053506 chromatographic step. The method involves adjusting the pH of the whey to a pH of 3.5-4 which can be achieved with a number of acids and adjusting the temperature to ~50C, such as 42-55C°C. The whey is then loaded to a cation exchanger for a prolonged period of time/volume after which a highly pure alpha-lactalbumin can be eluted from the column.
The novel aspect of the process is both in the simplicity of the process and the way in which the separation is achieved. The inventors have determined that at the described pH condition alphalactalbumin and beta-lactoglobulin both bind the cation exchanger. However, due to differences in charge and conformation at this condition alpha-lactalbumin is somewhat inhibited by mass transport limitations for which beta-lactoglobulin does not experience this effect means that the cation exchange medium must allow for equal access to available binding sites either by physical or kinetic limitation.
The inventors have found use of a large sized resin bead cation exchanger facilitates equal access at a defined contact or residence time with the cation exchanger. However, it could be estimated that other cation exchanger mediums and formats could facilitate the same capability including but not limited to chromatography membranes, open beds etc.
The other aspect of the invention that facilitates displacement of bound beta-lactoglobulin is by extension of the time/volume of whey loaded on to the cation exchanger. The combined effects of these allow separation by a single step and enable the replacement effect that occurs with alphalactalbumin displacing bound beta-lactoglobulin from the cation exchanger.
The method of the invention uses only a single chromatography step using only simple low cost buffers to achieve a high purity alpha-lactalbumin eluate > 80% (range 70 -95%) pure at a yield of 75% (range 65- 85%). In addition the alpha-lactalbumin depleted whey can be further processed for example pH adjusted back to a target set point, dried and recovered as a whey product or otherwise further processed.
There are several advantages with the method of the invention some of which are listed below:
- Process simplicity - single chromatography step - also means less buffers/ less programming requirement and shorter process time (though process time is sort of long)
- Works with simple buffers - providing pH and conductivity conditions are met almost any acid/base and salt can be used so low cost more economic options can be used
- High purity gives high value product with more utility can be used in more applications and high yield maximum recovery means less loss in process maximum return on investment and maximum utilization of material from feed material
WO 2018/149809
PCT/EP2018/053506
- Whey can still be used - requires additional processing but essentially process takes low cost product stream and extracts a higher cost product stream leaving the lower cost stream still useful.
Thus, the invention relates to a method for purification of whey proteins, comprising the following steps:
- providing a cation exchanger allowing for equal access of available binding sites by both alpha-lactalbumin and beta-lactoglobulin and complete replacement effect;
- acidifying a whey fraction;
- equilibrating said cation exchanger;
- loading said whey fraction on said cation exchanger;
- washing said cation exchanger; and
- eluting whey proteins from said cation exchanger.
Preferably the cation exchanger comprises chromatography beads having an average bead size diameter of 130-300 pm, preferably about 200 pm. In one embodiment the cation exchanger is packed in a column run with radial flow. The chromatography beads may be of natural or synthetic origin, preferably natural origin made of polysaccharides such as cellulose or agarose.
In the method of the invention the whey is acidified to a pH of 3.5-4.0, preferably pH 3.7. The equilibration and wash may be with 0.05-0.2% HAc or just water, but larger volumes are required or weaker acids, but also works with buffer system e.g. citric acid + Na2HPO4. Preferably the loading is performed at a linear velocity of 200 - 1000 cm/ and the method is preferably run at a temperature of 42-55°C, preferably about 50°C.
The elution is preferably a 1 step elution with 30-200 mM, preferably 75mM -125 mM NaOH or KOH. The eluate is preferably re-titrated from pH 12 to pH 4.5-8 This is to reconstitute the whey to its pH before acid titration, it is required to still use the rest of the whey protein that stayed in flow through.
The column may be cleaned in place (CIP) with IM NaOH /KOH at 50-60°C for >3 hours at high flow rates > 800 cm/h. The range is 100 - 800. First the flow rate is slow to avoid overpressure, later the high flow rate is required to wash out dirt most likely minerals that were covered with protein first.
The eluate obtained with the method of the invention comprises alfa-lactalbumin in a purity 70-95%, preferably 85-95%, and a yield of over 65-85%, preferably 75-85%. Other whey proteins may be collected in the flow through, such as beta-lactoglobulin.
WO 2018/149809
PCT/EP2018/053506
Brief description ofthe drawings
Figi is a schematic view of the one-step purification process of the invention.
Fig 2 is a chromatogram according to Experiment 1 in the Experimental section, showing the UV absorbance at 280 nm over the course ofthe process extracting alpha-lactalbumin from pH adjusted whey. The point at which beta-lactoblogulin can be seen to start to be displaced by alpha-lactalbumin can be observed at -400 L, at this point the level of beta in flow through exceeds that of the starting feed material.
Fig 3 is a chromatogram showing ion exchange analysis ofthe elution pool at 220 nm as described in Experiment 3 below.
FIG 4 is a chromatogram showing ion exchange analysis ofthe elution pool at 280 nm as described in Experiment 3 below.
Detailed description ofthe invention
The invention will now be described more closely in association with some non-limiting Examples and the accompanying drawings.
An overview ofthe process ofthe invention is described in Fig 1.
The invention described relates to a method of processing whey to obtain a purified alphalactalbumin or enriched alpha-lactalbumin whey protein isolate or fraction. The invention makes use of a cation exchanger that facilitates equal access to binding sites for alpha-lactalbumin and beta-lactoglobulin. In the examples given this is achieved by using a large bead cation exchange resin. However, other formats of chromatographic medium could be used that allow for equal access of available binding sites by both alpha-lactalbumin and beta-lactoglobulin. The cation exchange resin is appropriately packed into a column or suitable vessel in the example provided a radial flow column has been used to allow for high flow rates and decreased processing times. The cation exchanger is prepared for a run by use of a suitable equilibration buffer in the example 0.1% acetic acid is used.
The whey, ideal whey, acid whey, whey concentrate or whey isolates (all-inclusive whey protein product) are then adjusted to a pH between 3.5-4 with the optimum pH being 3.7. This pH adjustment can be performed using a number of acids however acetic, citric, phosphoric and HCI are suitable and compatible with the processing environment. This pH adjustment can be performed
WO 2018/149809
PCT/EP2018/053506 by several means either by in-line dilution, or by adjustment in a balance tank or other method. The required amount of acid needed to perform this adjustment can be easily determined by someone skilled in the art by performing a titration with the intended feed material. At this pH the proteins present in the whey undergo a number of changes due to the impacts of pH which interferes with tertiary and quaternary structural elements of protein structure causing change to function, denaturation and aggregation of some of the proteins. Under these conditions alpha-lactalbumin occurs in a molten globule form (Laureto et al, 2002, Rosner and Redfield, 2009).
The pH-adjusted whey protein product is then loaded onto the cation exchanger. In the example provided this is done using a large bead size cation exchange chromatography resin packed in a radial flow column. This can be done by use of a pump, positive displacement or other means so long as a consistent residence contact time is maintained. The flow rate required in the example is that required to achieve a contact time of 3-6 minutes, preferably about 4 minutes. This a critical element and is dependent on the properties of the cation exchanger used in other embodiments using other cation exchanger formats different requirements may exist. The period of time or volume of the loading phase is also a critical aspect of the invention as this aspect of the process allows alpha-lactalbumin to displace the bound beta-lactoglobulin and any other bound proteins. Fig 2 shows that the process of replacement takes place gradually over the loading phase. It is acknowledged by the inventors that a longer loading phase will result in higher purity alphalactalbumin and shorter loading phase will give an alpha-lactalbumin enriched whey protein isolate.
Table 1 below shows the amount of β-Lactaglobulin in flowthrough increases over the course of the run and exceeds the amount in the starting material as it is displaced from the column by aLactalbumin. a-Lactalbumin present in the flow through increases over the course of the run also however does not reflect a traditional breakthrough curve. Analysis of composite samples of flow through analysed using the method described in Experiment 2. The table shows the amount of alpha-lactalbumin relative to beta-lactoglobullin via sample analysis area vs starting feed whey area, area is calculated by mL x mAU as some UV Absorbance values were greater than 2 AU. It can be seen that both alpha-lactalbumin and beta-lactoglobulin initially bind the cation exchanger and then after a period of loading alpha-lactalbumin displaces bound beta-lactoglobulin in a replacement or displacement effect. This is seen as the level of beta-lactoglobulin in flow-through exceeds that of the starting feed material.
WO 2018/149809
PCT/EP2018/053506
Table 1
Sample | alphaLactalbumin (ml*mAU) | alphaLactalbumin Total AUC from integration window | beta- Lactoglobbulin (ml*mAU) | betalactaglobbulin Total AUC from integration window |
pH adjusted Whey | 1738 | 27.85% | 3776 | 60.50% |
0-90 CV | 120.6 | 9.53% | 859.8 | 67.10% |
90-180 CV | 237.9 | 5.48% | 3773 | 75.53% |
180-270 CV | 352.6 | 5.99% | 4465 | 75.90% |
270-360 CV | 546.1 | 9.86% | 4367 | 78.81% |
415 CV | 754.6 | 13.90% | 4226 | 77.86% |
The level of alpha-lactalbumin in the whey flow through can be measured by performing analysis using an analytical anion exchange or other suitable method however following process optimization time or volume set points can be used for simplified process operation.
Following the loading phase, a wash of any unbound materials in the column is performed this is a standard operation for any chromatographic method in the example presented as per the equilibration phase 0.1% acetic acid is used however there is many other suitable buffers including water.
Thereafter the elution of the bound alpha-lactalbumin is performed. Elution of the bound alphalactalbumin can be achieved by either displacement using an elution buffer a containing a suitable level of free positive ions or level of conductivity or by changing the charge of the bound protein by shifting the pH (with salt .e.g. NaCL or citrate or PCL). In the provided example this is achieved by use of KOH buffer at 22 mSc and pH 11. However there are many other suitable buffers including NaOH and others, the critical aspect being that the conductivity be > 10 mSc and pH > 5. However use of an elution buffer at these lower limits will elute the product much more slowly and a greater level of elution buffer will be required impacting upon the process economics and any downstream processing steps.
Following elution the eluate containing the highly pure alpha-lactalbumin can be pH adjusted back to 4-7 for further processing.
WO 2018/149809
PCT/EP2018/053506
EXPERIMENTAL SECTION
Experiment 1: Extraction of Alpha-Lactalbumin using SP Sepharose Big Beads in Radial Flow Column
This experiment was performed using SP Sepharose Big Beads (GE Healthcare) packed in a 21 L radial flow column. The column was first equilibrated with 0.1% Acetic acid, pH Adjustment of Whey was performed by the addition of 8.5% Phosphoric acid at 5% Whey volume. The pH adjusted Whey was then loaded onto the column at 5.25 L/min for an approximate 4 min residence time with a total of 105 column volumes. Following loading of the column a wash step prior to elution was performed with 0.1% Acetic acid with Elution of bound materials then performed with 125 mM NaOH. The point at which beta can be seen to start to be displaced by alpha can be observed at -400 L on the above Chromatogram, at this point the level of beta in flow through exceeds that of the starting feed material.
Equilibration | 5 CV 0.1% Acetic Flow rate 630L/hr (10.5 L/min, 2 min residence time) |
Loading | Whey pH adjusted to pH 3.7 with 8.5% Phosphoric acid Flow rate 315 L/hr (5.25L/min - 4 min residence time) 110 CV, Total loading 450 min - 2350 L |
Wash | 0.1% Acetic Flow rate 630 L/hr (10.5 L/min) 10 CV |
Elution | 125 mM NaOH Flow rate 630 L/hr (10.5 L/min) 25 CV |
Experiment 2 Analysis of the flow through stream- alpha lactalbumin depleted whey
Samples of the flow through from Experiment 1 were collected at intervals and analysed as per below.
WO 2018/149809
PCT/EP2018/053506
Parameter | |
FPLC | AKTA Pure 25M, with 10 mm path length multiwavelength UV detector (GE Healthcare). Tubing and connectors as required. |
Column | Guard Column - Source Q (GE Healthcare) Mono Q 5/50 GL (GE Healthcare) |
Buffers | Buffer A - 50 mM Tris pH 7.5 Buffer B - 50 mM Tris 450 mM NaCl pH 7.5 |
Equilibration | Buffer A - 50 mM Tris pH 7.5 unless stated 3CV @ 2.5 mL/min. |
Loading | Sample loaded by sample pump to 100 pL sample loop. Sample loop emptied with 1 mL sample. Sample injected from loop with 1 mL Buffer A onto column @ 2.5 mL/min, with pressure flow control. Temp 25C |
Wash | Buffer A - 50 mM Tris pH 7.5 unless stated 3CV @ 2.5 mL/min. |
Elution Gradient Step 1 | Buffer B -50 mM Tris 450 mM NaCl pH 7.5 0-63% gradient, Buffer B over 25 CV @ 2.5 mL/min. |
Elution Gradient Step 2 | Buffer B - 50 mM Tris 450 mM NaCl pH 7.5 63-100% gradient Buffer B over 3 CV @ 2.5 mL/min. |
Elution - Regen | Buffer B - 50 mM Tris 450 mM NaCl pH 7.5 3 CV @ 2.5 mL/min. |
Equilibration | Buffer A - 50 mM Tris pH 7.5 5CV @ 4 mL/min. |
The results of this experiment (Table 3) show how the amount of β-Lactaglobulin in flowthrough increases over the course ofthe run and exceeds the amount in the starting material as it is displaced from the column by a-Lactalbumin. a-Lactalbumin present in the flow through increases 5 over the course of the run also however does not reflect a traditional breakthrough curve. In this AEX assay there is enough resolution to differentiate between the two forms of a-Lactalbumin, molten (resolution at 11.5-12.5 mL) and native (resolution at 14.7 mL). Additionally, β-Lactaglobulin is also resolved into the two different forms.
WO 2018/149809
PCT/EP2018/053506
Table 2 below shows the purity of eluate pool of alpha-Lactalbumin as assessed using the technique described in Experiment 2 as measured at 220 nm and 280 nm UV absorbance.
Experiment | Purity (% total protein) Mono Q assay (220 nm Absorbance) | Purity (% total protein) Mono Q assay (280 nm Absorbance) |
1 | 82 | 91 |
Table 3 below shows the yield of material as assessed using the technique described in Experiment 2 as measured at 220 nm UV absorbance.
Experiment | Whey alphaLac Cone. (g/L) | Feed Load Vol (L) | Total alpha loaded to Column (g) | Eluate alpha-Lac Cone. (g/L) | Elution Vol (L) | Total alphaLac in collected Eluate pool (g) | Yield in Eluate Pool (%) |
1 | 1.55 | 2350 | 3653.80 | 5.41 | 500 | 2705.23 | 74.04 |
Experiment 3 Analysis of eluate pool purity by analytical ion exchange.
Samples of the composite eluate pool generated from Experiment 1 were analysed for purity
Parameter | |
FPLC | AKTA Pure 25M, with 10 mm path length multiwavelength UV detector (GE Healthcare). Tubing and connectors as required. |
Column | Guard Column - Source Q (GE Healthcare) Mono Q 5/50 GL (GE Healthcare) |
Buffers | Buffer A-50 mM Tris pH 7.5 Buffer B - 50 mM Tris 450 mM NaCl pH 7.5 |
Equilibration | Buffer A - 50 mM Tris pH 7.5 unless stated 3CV @ 2.5 mL/min. |
Loading | Sample loaded by sample pump to 100 pL sample loop. |
WO 2018/149809
PCT/EP2018/053506
Sample loop emptied with 1 mL sample. Sample injected from loop with 1 mL Buffer A onto column @ 2.5 mL/min, with pressure flow control. Temp 25C | |
Wash | Buffer A - 50 mM Tris pH 7.5 unless stated 3CV @ 2.5 mL/min. |
Elution Gradient Step 1 | Buffer B -50 mM Tris 450 mM NaCI pH 7.5 0-63% gradient, Buffer B over 25 CV @ 2.5 mL/min. |
Elution Gradient Step 2 | Buffer B - 50 mM Tris 450 mM NaCI pH 7.5 63-100% gradient Buffer B over 3 CV @ 2.5 mL/min. |
Elution - Regen | Buffer B - 50 mM Tris 450 mM NaCI pH 7.5 3 CV @ 2.5 mL/min. |
Equilibration | Buffer A-50 mM Tris pH 7.5 5CV @ 4 mL/min. |
The data shown in FIG 3 and FIG 4 was collected using the above method.
WO 2018/149809
PCT/EP2018/053506
References
Mayyada El-Sayed, Howard Chase, Single and two-component cation-exchange adsorption of the two pure majorwhey proteins, Journal of Chromatography A, 1216 (2009} 8705-8711
M.M.H.El-Sayed, HA.Chase. Purification of the two major proteins from whey concentrate using a cation-exchange selective adsorption process. J Biotechnology Progress, Vol.26, No.l, 2010, pp. 192199.
Kunz C, Lonnerdal B. Re-evaluation of the whey protein/casein ratio of human milk. Acta Paediatr 1992;81:107-12.
Heike I. Rosner and Christina Redfield, The Human a-Lactalbumin Molten Globule: Comparison of Structural Preferences at pH 2 and pH 7 J Mol Biol. 2009 Nov 27; 394(2-3): 351-362.
Maria Joao Santos, Jose A. Teixeira, Ligia R. Rodrigues, Fractionation of the major whey proteins and isolation of b-Lactoglobulin variants by anion exchange chromatography, Separation and Purification Technology 90 (2012) 133-139.
Samuel Mburu Kamau, Seronei Chelulei Cheison, Wei Chen, Xiao-Ming Liu, and Rong-Rong Lu, Alpha-Lactalbumin: Its Production Technologies and Bioactive Peptides, Vol. 9, 2010— COMPREHENSIVE REVIEWS IN FOOD SCIENCE AND FOOD SAFETY.
NICOLETA STANCIUC, GABRIELA RAPEANU, AN OVERVIEW OF BOVINE a-LACTALBUMIN STRUCTURE AND FUNCTIONALITY, The Annals of the University Dunarea de Jos of Galati Fascicle VI - Food Technology, 34(2).
Katarina Lisak Jakopovic* Irena Barukclc, Rajka Bozanic, Physiological significance, structure and isolation of a-lactalbumin, Mljekarstvo 66 (1), 3-11 (2016)
Marshall K. 2004. Therapeutic applications of whey protein. Altern Med Rev 9:136-56.
Laureto PPD, Frare E, Battaglia F, Mossuto MF, Uversky VN, Fontana A. 2005. Protein dissection enhances the amyloidogenic properties of a-lactalbumin. FEBS J 272:2176- 88.
PATRIZIA POLVERINO DE LAURETO,1 ERICA FRARE,1 ROSSELLA GOTTARDO.l HERMAN VAN DAEL,2 AND ANGELO F0NTANA1, Partly folded states of members of the Lysozyme/lactalbumin superfamily: A comparative study by circular dichroism spectroscopy and limited proteolysis, Protein Science (2002), 11:2932-2946.
WO 2018/149809
PCT/EP2018/053506
Claims (5)
1. A method for purification of whey proteins, comprising the following steps:
- providing a cation exchanger allowing for equal access of available binding sites by both alpha-lactalbumin and beta-lactoglobulin and complete replacement effect;
- acidifying a whey fraction;
- equilibrating said cation exchanger;
- loading said whey fraction on said cation exchanger;
- washing said cation exchanger; and
- eluting whey proteins from said cation exchanger.
2. Method according to claim 1, wherein the cation exchanger comprises chromatography beads having an average bead size diameter of 130-300 pm, preferably about 200 pm.
3. Method according to claim 1 or 2, wherein the cation exchanger is packed in a column run with radial flow.
4. Method according to claim 1, 2 or 3, wherein the whey is acidified to a pH of 3.5-4.0, preferably pH 3.7.
5. Method according to claim 4, wherein the acidifying is with H3PO4, HCI, HAc, or Citric acid.
6. Method according to one or more of the above claims, wherein equilibration and wash is with 0.05-0.2% HAc.
7. Method according to one of more of the above claims, wherein the loading is performed at a linear velocity of 200 - 1000 cm/h.
8. Method according to one of more of the above claims, wherein the process is run at a temperature of 42-55°C, preferably about 50°C.
9. Method according to one or more of the above claims, wherein the elution is 1 step elution with 30-200 mM, preferably 75mM -125 mM NaOH or KOH.
10. Method according to one or more ofthe above claims, wherein the eluate is retitrated from pH 12 to pH 4.5-8.
11. Method according to one or more ofthe above claims, wherein the column is cleaned in place (CIP) with IM NaOH /KOH at 50-60°C for >3 hours at high flow rates > 800 cm/h.
WO 2018/149809 PCT/EP2018/053506
12. Method according to one or more of the above claims, wherein the eluate comprises alfa lactalbumin in a purity 70-95%, preferably 85-95%, and a yield of over 65-85%, preferably 75-85%.
5 13. Method according to one or more of the above claims, wherein other whey proteins are collected in the flow through, such as beta-lactoglobulin.
WO 2018/149809
PCT/EP2018/053506
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1702499.3 | 2017-02-16 | ||
GBGB1702499.3A GB201702499D0 (en) | 2017-02-16 | 2017-02-16 | Methods for purification of whey proteins |
PCT/EP2018/053506 WO2018149809A1 (en) | 2017-02-16 | 2018-02-13 | Method for purification of whey proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2018221613A1 true AU2018221613A1 (en) | 2019-08-08 |
Family
ID=58486777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018221613A Pending AU2018221613A1 (en) | 2017-02-16 | 2018-02-13 | Method for purification of whey proteins |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3583114A1 (en) |
CN (2) | CN117402229A (en) |
AU (1) | AU2018221613A1 (en) |
GB (1) | GB201702499D0 (en) |
WO (1) | WO2018149809A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096870A (en) * | 1994-01-05 | 2000-08-01 | Sepragen Corporation | Sequential separation of whey |
AU4589397A (en) * | 1997-09-22 | 1999-04-12 | Sepragen Corporation | Sequential separation of whey proteins and formulations thereof |
DK1748701T3 (en) * | 2004-05-07 | 2010-09-20 | Wisconsin Alumni Res Found | Methods and compositions involving whey protein isolates |
EP2355664B8 (en) * | 2008-09-30 | 2014-09-10 | Upfront Chromatography A/S | A Method for Providing a beta-Lactoglobulin Product and an alpha-enriched Whey Protein Isolate |
CN102286096A (en) * | 2011-07-08 | 2011-12-21 | 上海交通大学 | Scale purification method for lactalbumin |
CN104513305B (en) * | 2013-09-27 | 2017-11-21 | 北京济普霖生物技术有限公司 | A kind of purification process of lactalbumin |
-
2017
- 2017-02-16 GB GBGB1702499.3A patent/GB201702499D0/en not_active Ceased
-
2018
- 2018-02-13 CN CN202311332100.XA patent/CN117402229A/en active Pending
- 2018-02-13 EP EP18705372.3A patent/EP3583114A1/en active Pending
- 2018-02-13 AU AU2018221613A patent/AU2018221613A1/en active Pending
- 2018-02-13 CN CN201880012175.0A patent/CN110267968B/en active Active
- 2018-02-13 WO PCT/EP2018/053506 patent/WO2018149809A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110267968A (en) | 2019-09-20 |
GB201702499D0 (en) | 2017-04-05 |
CN110267968B (en) | 2024-01-30 |
EP3583114A1 (en) | 2019-12-25 |
CN117402229A (en) | 2024-01-16 |
WO2018149809A1 (en) | 2018-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Almécija et al. | Effect of pH on the fractionation of whey proteins with a ceramic ultrafiltration membrane | |
Santos et al. | Fractionation of the major whey proteins and isolation of β-Lactoglobulin variants by anion exchange chromatography | |
Korhonen et al. | Technological options for the production of health-promoting proteins and peptides derived from milk and colostrum | |
FI91032C (en) | Method for recovering pure fractions of lactoperoxidase and lactoferrin from milk serum | |
US6010698A (en) | Process for recovering growth factors, or a composition containing one or more growth factors, from milk or a milk derivative | |
AU2012222312B2 (en) | Method for isolating osteopontin using feeds containing cmp or casein species | |
Kaur et al. | Recent developments in purification techniques and industrial applications for whey valorization: A review | |
US9247766B2 (en) | Angiogenin-enriched milk fractions | |
Goodall et al. | Selective separation of the major whey proteins using ion exchange membranes | |
US5986063A (en) | Isolating β-lactoglobulin and α-lactalbumin by eluting from a cation exchanger without sodium chloride | |
Bonnaillie et al. | Whey protein fractionation | |
Abd El-Salam et al. | Separation of bioactive whey proteins and peptides | |
US20170318835A1 (en) | Method for separating alpha-lactalbumin and beta-lactoglobulin | |
Wu et al. | Isolation and purification of lactoferrin and immunoglobulin G from bovine colostrum with serial cation-anion exchange chromatography | |
AU2018221613A1 (en) | Method for purification of whey proteins | |
KR20150091329A (en) | Method of producing a composition containing caseinomacropeptide | |
US20170295821A1 (en) | Isolation of soluble proteins from aggregated casein-containing mixtures | |
Ottens et al. | Advances in process chromatography and applications in the food, beverage and nutraceutical industries | |
Wu et al. | Isolation and purification of bioactive proteins from bovine colostrum | |
Fee et al. | Methods for purification of dairy nutraceuticals | |
Stanic et al. | Application of ion exchanger in the separation of whey proteins and lactin from milk whey | |
AU1313401A (en) | Method of obtaining immunoglobulins from colostrum and dairy sources | |
WO2024056840A1 (en) | Isolation of osteopontin and glycomacropeptide from whey | |
Gésan-Guiziou | Extraction of Functional Food Ingredients and Nutraceuticals from Dairy | |
AU2022263624A1 (en) | Whey protein-containing product enriched in immunoglobulins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HB | Alteration of name in register |
Owner name: CYTIVA BIOPROCESS R&D AB Free format text: FORMER NAME(S): GE HEALTHCARE BIOPROCESS R&D AB |